<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052078</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH064089</org_study_id>
    <secondary_id>U01MH064089</secondary_id>
    <secondary_id>DSIR 84-CTP</secondary_id>
    <nct_id>NCT00052078</nct_id>
  </id_info>
  <brief_title>Child and Adolescent Anxiety Disorders (CAMS)</brief_title>
  <official_title>Child/Adolescent Anxiety Multimodal Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      This randomized, controlled trial compared the efficacy of the medication sertraline
      (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for
      youth with anxiety disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are among the most common conditions affecting children and adolescents.
      These disorders impair school, social, and family functioning. When left untreated, they also
      put children at risk for major depression and substance abuse in late adolescence and
      adulthood. Previous studies demonstrated the efficacy of cognitive behavioral therapy and
      selective serotonin-reuptake inhibitors for the treatment of child anxiety disorders. This
      study is testing the relative and combined efficacy of cognitive behavioral therapy and
      selective serotonin reuptake inhibitors as compared to each other and pill placebo.

      During Phase I of this two-phase study, 488 participants were randomly assigned to receive
      sertraline (Zoloft), cognitive behavioral therapy, a combination of these treatments, or a
      placebo for 12 weeks. Phase II involved a 6-month maintenance period for participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression - Improvement Scale</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1-Very much improved; 2-Much improved; 3-Minimally improved; 4-No change; 5-Minimally worse; 6-Much worse; 7-Very much worse. Response rates are reported as a percentage of participants who score 1-Very much improved; 2-Much improved on the The Clinical Global Impression - Improvement scale.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Anxiety Disorders</condition>
  <condition>Social Phobia</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received sertraline for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received cognitive behavioral therapy for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRT + CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received both sertraline and CBT for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a placebo pill for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline (SRT)</intervention_name>
    <description>Participants were treated with sertraline.</description>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_label>SRT + CBT</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>Participants received CBT.</description>
    <arm_group_label>CBT</arm_group_label>
    <arm_group_label>SRT + CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants were treated with a placebo pill.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for separation
             anxiety disorder, social phobia, or generalized anxiety disorder

        Exclusion Criteria:

          -  Major neurological disorder or medical illness that would interfere with participation
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYSPI/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh/WPIC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 Dec 25;359(26):2753-66. doi: 10.1056/NEJMoa0804633. Epub 2008 Oct 30. Erratum in: N Engl J Med. 2013 Jan 31;368(5):490.</citation>
    <PMID>18974308</PMID>
  </results_reference>
  <results_reference>
    <citation>Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, March J, Sherrill J, Sakolsky D, Ginsburg G, Rynn M, Bergman RL, Gosch E, Waslick B, Iyengar S, McCracken J, Walkup J. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014 Mar;53(3):297-310. doi: 10.1016/j.jaac.2013.11.010. Epub 2013 Nov 28.</citation>
    <PMID>24565357</PMID>
  </results_reference>
  <results_reference>
    <citation>Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, Walkup JT, Sherrill J, Coffey KA, Rynn MA, Keeton CP, McCracken JT, Bergman L, Iyengar S, Birmaher B, March J. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011 Dec;79(6):806-13. doi: 10.1037/a0025933.</citation>
    <PMID>22122292</PMID>
  </results_reference>
  <results_reference>
    <citation>Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B, Sherrill JT, Ginsburg GS, Rynn MA, McCracken JT, Waslick BD, Iyengar S, Kendall PC, March JS. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health. 2010 Jan 5;4:1. doi: 10.1186/1753-2000-4-1.</citation>
    <PMID>20051130</PMID>
  </results_reference>
  <results_reference>
    <citation>Compton SN, Peris TS, Almirall D, Birmaher B, Sherrill J, Kendall PC, March JS, Gosch EA, Ginsburg GS, Rynn MA, Piacentini JC, McCracken JT, Keeton CP, Suveg CM, Aschenbrand SG, Sakolsky D, Iyengar S, Walkup JT, Albano AM. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol. 2014 Apr;82(2):212-24. doi: 10.1037/a0035458. Epub 2014 Jan 13.</citation>
    <PMID>24417601</PMID>
  </results_reference>
  <results_reference>
    <citation>Kendall PC, Compton SN, Walkup JT, Birmaher B, Albano AM, Sherrill J, Ginsburg G, Rynn M, McCracken J, Gosch E, Keeton C, Bergman L, Sakolsky D, Suveg C, Iyengar S, March J, Piacentini J. Clinical characteristics of anxiety disordered youth. J Anxiety Disord. 2010 Apr;24(3):360-5. doi: 10.1016/j.janxdis.2010.01.009. Epub 2010 Feb 6.</citation>
    <PMID>20206470</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2003</study_first_submitted>
  <study_first_submitted_qc>January 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2003</study_first_posted>
  <results_first_submitted>July 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phobic Disorders</keyword>
  <keyword>Anxiety, Separation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Setraline</title>
          <description>Participants will receive sertraline for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>2 CBT</title>
          <description>Participants will receive cognitive behavioral therapy for 12 weeks
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>3 Combination Setraline and CBT</title>
          <description>Participants will receive a combination of sertraline and cognitive behavioral therapy for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>4 Placebo</title>
          <description>Participants will receive placebo for 12 weeks
Placebo: Participants will take placebo capsules for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Setraline</title>
          <description>Participants will receive sertraline for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>2 CBT</title>
          <description>Participants will receive cognitive behavioral therapy for 12 weeks
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>3 Combination Setraline and CBT</title>
          <description>Participants will receive a combination of sertraline and cognitive behavioral therapy for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>4 Placebo</title>
          <description>Participants will receive placebo for 12 weeks
Placebo: Participants will take placebo capsules for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="140"/>
            <count group_id="B4" value="76"/>
            <count group_id="B5" value="488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression - Improvement Scale</title>
        <description>The Clinical Global Impression – Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1-Very much improved; 2-Much improved; 3-Minimally improved; 4-No change; 5-Minimally worse; 6-Much worse; 7-Very much worse. Response rates are reported as a percentage of participants who score 1-Very much improved; 2-Much improved on the The Clinical Global Impression – Improvement scale.</description>
        <time_frame>Measured at Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Setraline</title>
            <description>Participants will receive sertraline for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2 CBT</title>
            <description>Participants will receive cognitive behavioral therapy for 12 weeks
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>3 Combination Setraline and CBT</title>
            <description>Participants will receive a combination of sertraline and cognitive behavioral therapy for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>4 Placebo</title>
            <description>Participants will receive placebo for 12 weeks
Placebo: Participants will take placebo capsules for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression - Improvement Scale</title>
          <description>The Clinical Global Impression – Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1-Very much improved; 2-Much improved; 3-Minimally improved; 4-No change; 5-Minimally worse; 6-Much worse; 7-Very much worse. Response rates are reported as a percentage of participants who score 1-Very much improved; 2-Much improved on the The Clinical Global Impression – Improvement scale.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="46.4" upper_limit="63.1"/>
                    <measurement group_id="O2" value="59.7" lower_limit="51.4" upper_limit="67.5"/>
                    <measurement group_id="O3" value="80.7" lower_limit="73.3" upper_limit="86.4"/>
                    <measurement group_id="O4" value="23.7" lower_limit="15.5" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Setraline</title>
          <description>Participants will receive sertraline for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>2 CBT</title>
          <description>Participants will receive cognitive behavioral therapy for 12 weeks
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>3 Combination Setraline + CBT</title>
          <description>Participants will receive a combination of sertraline and cognitive behavioral therapy for 12 weeks
Sertraline: Participants will take sertraline for 12 weeks.
Cognitive Behavioral Therapy (CBT): Participants will receive CBT for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>4 Placebo</title>
          <description>Participants will receive placebo for 12 weeks
Placebo: Participants will take placebo capsules for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Behavior</sub_title>
                <description>One participant in the sertraline group had a worsening of behavior that was attributed to the parents' increased limit setting on avoidance behavior; the event was considered to be possibly related to sertraline.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Oppositional-Defiant Behavior</sub_title>
                <description>One participant in the combination-therapy group had a worsening of preexisting oppositional-defiant behavior that resulted in psychiatric hospitalization; this event was considered to be unrelated to study treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <description>One participant in the sertraline group was medically hospitalized for a tonsillectomy. This event was considered unrelated to study treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Walkup</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>212-746-1891</phone>
      <email>jtw9001@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

